Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
205.14 x 100 209.57 x 100
Post-market by (Cboe BZX)
206.27 -3.25 (-1.55%) 04/01/25 [NYSE]
205.14 x 100 209.57 x 100
Post-market 207.98 +1.71 (+0.83%) 18:23 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
205.60
Day High
212.15
Open 210.52
Previous Close 209.52 209.52
Volume 7,853,200 7,853,200
Avg Vol 7,079,100 7,079,100
Stochastic %K 54.54% 54.54%
Weighted Alpha +23.40 +23.40
5-Day Change +4.93 (+2.45%) +4.93 (+2.45%)
52-Week Range 153.58 - 218.66 153.58 - 218.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 370,636,288
  • Shares Outstanding, K 1,768,978
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,130 M
  • EBITDA $ 17,516 M
  • 60-Month Beta 0.61
  • Price/Sales 6.45
  • Price/Cash Flow 13.75
  • Price/Book 107.84

Options Overview Details

View History
  • Implied Volatility 29.17% ( +0.59%)
  • Historical Volatility 20.49%
  • IV Percentile 95%
  • IV Rank 91.50%
  • IV High 30.36% on 10/29/24
  • IV Low 16.36% on 05/10/24
  • Put/Call Vol Ratio 1.91
  • Today's Volume 28,287
  • Volume Avg (30-Day) 25,709
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 379,475
  • Open Int (30-Day) 365,870

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.51
  • Number of Estimates 9
  • High Estimate 2.61
  • Low Estimate 2.48
  • Prior Year 2.31
  • Growth Rate Est. (year over year) +8.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
196.49 +4.98%
on 03/26/25
Period Open: 209.03
218.66 -5.67%
on 03/10/25
-2.76 (-1.32%)
since 02/28/25
3-Month
168.06 +22.74%
on 01/22/25
Period Open: 177.70
218.66 -5.67%
on 03/10/25
+28.57 (+16.08%)
since 12/31/24
52-Week
153.58 +34.31%
on 05/30/24
Period Open: 180.76
218.66 -5.67%
on 03/10/25
+25.51 (+14.11%)
since 04/01/24

Most Recent Stories

More News
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.

Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.

ABT : 131.69 (-0.72%)
MRK : 87.12 (-2.94%)
SMMT : 18.80 (-2.54%)
ABBV : 206.27 (-1.55%)
ISRG : 496.36 (+0.22%)
MarketBeat Week in Review – 03/24 - 03/28

Markets got a double dose of bad news about inflation and consumer confidence; next week, the Trump tariffs and Jobs report are likely to keep volatility high

CELH : 35.73 (+0.31%)
NVDA : 110.15 (+1.63%)
GOOGL : 157.07 (+1.57%)
META : 586.00 (+1.67%)
SMCI : 35.05 (+2.37%)
BRK-A : N/A (N/A)
MDB : 176.61 (+0.69%)
ABBV : 206.27 (-1.55%)
LUNR : 7.47 (+0.27%)
OXY : 49.19 (-0.34%)
ACHR : 6.96 (-2.11%)
TSLA : 268.46 (+3.59%)
3 Relatively Safe Stocks to Buy Right Now

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions.

ABT : 131.69 (-0.72%)
JNJ : 153.25 (-7.59%)
ABBV : 206.27 (-1.55%)
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?

Following the crowd has been disparaged quite a bit in the past. But sometimes the crowd knows what it's doing. Going in the same direction in those cases is wise.

VHT : 259.93 (-1.81%)
CVX : 168.51 (+0.73%)
CEG : 206.94 (+2.63%)
COP : 105.39 (+0.35%)
JNJ : 153.25 (-7.59%)
ABBV : 206.27 (-1.55%)
AEP : 108.37 (-0.82%)
WMB : 60.57 (+1.36%)
UNH : 523.12 (-0.12%)
NEE : 70.92 (+0.04%)
ABT : 131.69 (-0.72%)
VDE : 130.35 (+0.49%)
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income

Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility, including AbbVie...

ABT : 131.69 (-0.72%)
ABBV : 206.27 (-1.55%)
3 Healthcare Stocks in the Doghouse

3 Healthcare Stocks in the Doghouse

BLCO : 14.10 (-2.76%)
IRTC : 106.88 (+2.10%)
ABBV : 206.27 (-1.55%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 6.0500 (+0.50%)
NVO : 68.03 (-2.03%)
NVS : 109.61 (-1.68%)
ABBV : 206.27 (-1.55%)
PFE : 24.54 (-3.16%)
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

SRPT : 61.91 (-2.99%)
BMRN : 67.94 (-3.89%)
ABBV : 206.27 (-1.55%)
MRNA : 27.16 (-4.20%)
BIIB : 132.03 (-3.52%)
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

GCTK : 0.2250 (+28.94%)
TCBP : 0.5000 (-67.53%)
ABBV : 206.27 (-1.55%)
ATNM : 1.4900 (-7.45%)
RGC : 28.99 (-9.07%)
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

NVO : 68.03 (-2.03%)
LLY : 805.23 (-2.50%)
ABBV : 206.27 (-1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 216.96
2nd Resistance Point 214.56
1st Resistance Point 210.41
Last Price 206.27
1st Support Level 203.86
2nd Support Level 201.46
3rd Support Level 197.31

See More

52-Week High 218.66
Last Price 206.27
Fibonacci 61.8% 193.80
Fibonacci 50% 186.12
Fibonacci 38.2% 178.44
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies